Home › Research › Risk factors
Regional variability of the impact of cardiometabolic diseases on incident dementia in United States Medicare beneficiaries
George K. Karway, Brittany Krzyzanowski, Jordan A. Killion, Irene M. Faust, Osvaldo Laurido-Soto, Marwan Noel Sabbagh, Brad Alan Racette. Alzheimer s & Dementia, 2025-05-01
Topic: Risk, prevention and care in population studies
Plain-language summary
The nationwide combined weighted PAF for the eight CMDs was 37% overall, with hypertension (9.6%), ischemic heart disease (6.7%), and chronic heart failure (5.7%) associated with the greatest attributable fractions of dementia cases. The greatest fraction of county-level dementia cases attributed to CMDs were in the Southeastern United States. A substantial proportion of incident dementia cases in the United States can be attributed to CMDs, especially in the Southeastern United States. HIGHLIGHTS: Investigated the combined effect of cardiometabolic diseases (CMDs) on dementia. Used novel geospatial techniques to map the burden of dementia attributed to CMDs. If eight CMDs are mitigated, 37% of incident dementia cases could be eliminated. Identified regions of the United States with high CMD burden on dementia.
What this study adds
Evidence grade: Low
The authors state that if these eight conditions were mitigated, 37% of incident dementia cases could be eliminated, but this is an estimate of attributable burden, not proof that treating these conditions prevents dementia. Reported effect size: 9.6%; 6.7%; 5.7%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Karway, G. K., Krzyzanowski, B., Killion, J. A., Faust, I. M., Laurido-Soto, O., Sabbagh, M. N., et al. (2025). Regional variability of the impact of cardiometabolic diseases on incident dementia in United States Medicare beneficiaries. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70199
Vancouver
Karway GK, Krzyzanowski B, Killion JA, Faust IM, Laurido-Soto O, Sabbagh MN, et al. Regional variability of the impact of cardiometabolic diseases on incident dementia in United States Medicare beneficiaries. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70199. PMID: 40407074.
BibTeX
@article{karway2025-40407074,
author = {Karway, George K. and Krzyzanowski, Brittany and Killion, Jordan A. and Faust, Irene M. and Laurido-Soto, Osvaldo and Sabbagh, Marwan Noel and Racette, Brad Alan},
title = {{Regional variability of the impact of cardiometabolic diseases on incident dementia in United States Medicare beneficiaries}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.70199},
pmid = {40407074},
url = {https://doi.org/10.1002/alz.70199}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- The nationwide combined weighted PAF for the eight CMDs was 37% overall, with hypertension (9.6%), ischemic heart disease (6.7%), and chronic heart failure (5.7%) associated with the greatest attributable fractions of dementia cases.
- The greatest fraction of county-level dementia cases attributed to CMDs were in the Southeastern United States.
- A substantial proportion of incident dementia cases in the United States can be attributed to CMDs, especially in the Southeastern United States.
- HIGHLIGHTS: Investigated the combined effect of cardiometabolic diseases (CMDs) on dementia.
- Used novel geospatial techniques to map the burden of dementia attributed to CMDs.
Why it matters
This analysis estimated that eight cardiometabolic diseases together accounted for 37% of new dementia cases in US Medicare beneficiaries, with hypertension, ischemic heart disease, and chronic heart failure contributing the most, and the highest burden in the Southeastern United States. The authors state that if these eight conditions were mitigated, 37% of incident dementia cases could be eliminated, but this is an estimate of attributable burden, not proof that treating these conditions prevents dementia.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Effect size9.6%; 6.7%; 5.7%
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Brad Alan Racette: h-index 51 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40407074) |
| Free to read | 2 / 2 | Free to read |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Risk factors from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.